Mice were received sorafenib by gavage one day before ACT followed by four consecutive doses; the activation of transferred pGBeLT-transduced CD8+ T cells and tumor growth monitoring by BLI and caliper measurement were performed, respectively (Figure 5A). Here, CD8A is linked to neoplasm.